このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

NF1-PN の小児患者におけるセルメチニブの効果と安全性を評価する観察研究 (PEDIA)

2026年9月22日 更新者:AstraZeneca

症候性で手術不能な神経線維腫症1型(NF1)関連叢状神経線維腫(PN)の小児患者におけるMEK 1/2阻害剤(MEKi)コセルゴ(セルメチニブ)の有効性と安全性に関する観察研究

This is a prospective, multicenter, observational study of Chinese pediatric NF1-PN patients treated with selumetinib. The study will be conducted at approximately 12 centers in China and will include approximately 80-100 patients. Treatment centers that have PN diagnosis and/or selumetinib treatment experience will be targeted for recruitment. Patients/caregivers who are eligible and willing to participate will be enrolled into the study. Patients will start selumetinib treatment after enrollment. The study will have a 16-month enrollment period. Patients will be followed up until the end of a 24-month observation period after first dose of selumetinib, or patient death, lost to follow-up, withdrawal of consent, whichever occurs first. Patients will be followed within a 24-month period (starting after first dose received) in the study even if selumetinib is discontinued. The aims of this study are to expand understanding of disease characteristics and treatment pattern of NF1-PN in China in a real-world setting and to evaluate real-world effectiveness and safety of selumetinib for Chinese pediatric patients with NF1-PN

調査の概要

状態

積極的、募集していない

詳細な説明

Neurofibromatosis type 1 (NF1) is a rare and incurable autosomal dominant genetic disorder that is characterized by manifestations in multiple organ systems including tumors of the nervous system. Although NF1 is inherited via autosomal dominance, 50% of detected mutations are de novo. The population prevalence of NF1 estimates ranging from approximately 1/2000 to 1/4000 , and there are estimated 460,000 patients in China. The condition is usually recognized in early childhood, when pigmentary manifestations emerge. NF1 patients have decreased life expectancy of 15 years compared to the general population. High-grade glioma (HGG) and malignant peripheral nerve sheath tumor (MPNST) were noteworthy causes of death among patients with NF1.

Plexiform neurofibromas (PN) are tumors arise from Schwann cells of peripheral, visceral, or subcutaneous nerves, affecting 30%-50% of patients with NF1. PN can cause substantial complications including pain, functional impairment, disfigurement and have a risk of malignant transformation. The lifetime incidence of MPNST in patients with NF1 is 8%-13% , and the presence of a PN elevates the risk of MPNST formation by 20-fold among NF1 patients. Most PN are diagnosed in early childhood and grow most rapidly during this period. Surgical resection is the mainstay treatment for PN, yet surgical treatment does not have satisfactory effect. Complete surgical resection of these tumors is often infeasible due to the extensive growth of the tumor and invasion of surrounding tissues, and partial removal often comes with a high recurrence rate. Conventional chemotherapy and radiotherapy have shown limited efficacy for NF1-associated PN. As a result, medical therapies targeting PN have been evaluated in clinical trials.

The therapeutic revolution came in 2020 with the approval of selumetinib for pediatric patients with NF1-associated PN. Selumetinib is an oral selective inhibitor of MEK 1 and 2 and has been confirmed effective for NF1-associated PN in SPRINT Phase II Stratum 1. The overall response rate was 68% (34/50), and 82% (28/34) of these patients had a durable response (lasting ≥12 months) (Gross AM et al, 2020). Selumetinib was approved by the United States Food and Drug Administration (US-FDA) on April 10, 2020, becoming the first approved targeted therapy for pediatric patients with NF1-associated PN. On April 28, 2023, the China National Medical Products Administration (NMPA) approved selumetinib for pediatric patients aged 3 years and older diagnosed with NF1 who have symptomatic, inoperable PN.

To date, evidence on real-world data of clinical benefit of selumetinib for NF1-associated PN patients among Chinese population is lacking. Moreover, due to the relatively rare affected population, disease knowledge of NF1 and PN is limited among healthcare professionals (HCPs) and throughout the society. An observational study of pediatric patients with NF1-associated PN treated with selumetinib in China will fulfill the data gap of effectiveness and safety of selumetinib for Chinese NF1-PN patients and will facilitate the understanding of disease characteristics and treatment in this population in a real-world setting.

Observational Study of the Effectiveness and Safety of the MEK 1/2 Inhibitor (MEKi) Koselugo (Selumetinib) in Pediatric Patients with Symptomatic, Inoperable, Neurofibromatosis Type 1 (NF1)-Associated Plexiform Neurofibromas (PN) . The aims of this study are to expand understanding of disease characteristics and treatment pattern of NF1-PN in China in a real-world setting and to evaluate real-world effectiveness and safety of selumetinib for Chinese pediatric patients with NF1-PN. This is a prospective, multicenter, observational study of Chinese pediatric NF1-PN patients treated with selumetinib. The study will be conducted at approximately 12 centers in China and will include approximately 80-100 patients (ie, at least 80 patients will be enrolled into the study, but should not enrol more than 100 patients within 16 months). Treatment centers that have PN diagnosis and/or selumetinib treatment experience will be targeted for recruitment. Patients/caregivers who are eligible and willing to participate will be enrolled into the study. Patients will start selumetinib treatment after enrollment.

The study will have a 16-month enrollment period. Patients will be followed up until the end of a 24-month observation period after first dose of selumetinib, or patient death, lost to follow-up, withdrawal of consent, whichever occurs first. Patients will be followed within a 24-month period (starting after first dose received) in the study even if selumetinib is discontinued. Pediatric patients with neurofibromatosis type 1 (NF1) aged 3-16 years (3 and 16 years are inclusive) who have symptomatic, inoperable plexiform neurofibromas (PN) and intend to use selumetinib after enrollment. Approximately 80-100 eligible patients will be enrolled in the study. Exposure to selumetinib is of interest for this study. Based on prescribing information, the recommended dosage of selumetinib is 25 mg/m2 orally twice daily (approximately every 12 hours) until disease progression, unacceptable toxicity, risk or no longer benefit from selumetinib treatment in the judgement of physicians, or the end of 24-month follow-up period, whichever occurs first. After 24-month follow-up period, whether the patients continue exposure to selumetinib will not be collected. Based on the study purpose, the following outcomes will be collected or measured: Patient demographics and disease characteristics at baseline and during selumetinib treatment

Treatment profile with selumetinib

Effectiveness outcomes of selumetinib

Safety outcomes of selumetinib

Time to tumor regrowth after selumetinib discontinuation

Disease and treatment course after selumetinib discontinuation

Caregiver- or patient-reported selumetinib treatment adherence

Patient-reported pain intensity.

研究の種類

観察的

入学 (実際)

409

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Nanjing、中国
        • Research Site
    • Beijing Municipality
      • Beijing、Beijing Municipality、中国
        • Research Site
    • Chongqing Municipality
      • Chongqing、Chongqing Municipality、中国
        • Research Site
    • Gansu
      • Lanzhou、Gansu、中国
        • Research Site
    • Guangdong
      • Guangzhou、Guangdong、中国
        • Research Site
      • Shenzhen、Guangdong、中国
        • Research Site
    • Guangxi
      • Nanning、Guangxi、中国
        • Research Site
    • Guizhou
      • Guiyang、Guizhou、中国
        • Research Site
    • Hebei
      • Shijiazhuang、Hebei、中国
        • Research Site
    • Henan
      • Zhengzhou、Henan、中国
        • Research Site
    • Hubei
      • Wuhan、Hubei、中国
        • Research Site
    • Hunan
      • Changsha、Hunan、中国
        • Research Site
    • Jiangsu
      • Nanjing、Jiangsu、中国
        • Research Site
      • Suzhou、Jiangsu、中国
        • Research Site
    • Jiangxi
      • Nanchang、Jiangxi、中国
        • Research Site
    • Liaoning
      • Shenyang、Liaoning、中国
        • Research Site
    • Shandong
      • Jinan、Shandong、中国
        • Research Site
    • Shanghai Municipality
      • Shanghai、Shanghai Municipality、中国
        • Research Site
    • Shanxi
      • Taiyuan、Shanxi、中国
        • Research Site
      • Xi’an、Shanxi、中国
        • Research Site
    • Sichuan
      • Chengdu、Sichuan、中国
        • Research Site
    • Tianjin Municipality
      • Tianjin、Tianjin Municipality、中国
        • Research Site
    • Yunnan
      • Kunming、Yunnan、中国
        • Research Site
    • Zhejiang
      • Hangzhou、Zhejiang、中国
        • Research Site
      • Wenzhou、Zhejiang、中国
        • Research Site

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

3年~16年 (子)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

The target population of interest in this study is pediatric patients with neurofibromatosis type 1 (NF1) aged 3-16 years (3 and 16 years are inclusive) who have symptomatic, inoperable plexiform neurofibromas (PN) and intend to use selumetinib after enrollment. Each eligible patient should meet all of the inclusion criteria and none of the exclusion criteria. At least 80 and no more than 100 eligible patients will be enrolled in the study.

説明

Inclusion Criteria:

  • (1) 3≤ age ≤16 years old at the time of study enrollment; (2) Diagnosed with NF1 as per the revised 2021 Guidelines; (3) Have symptomatic, inoperable PN: (4) Intend to use selumetinib after enrollment; (5) Able to give written informed consent. Data collection must only be done after obtaining written informed consent. Patient or patient's parent/legal guardian must be willing and able to give written informed consent. Parent or legal guardian consent is required in the assent process with appropriate documentation. Mandatory provision of signed and dated parent/legal guardian consent for the study along with the pediatric assent form, when applicable.

Exclusion Criteria:

  • (1) Evidence of MPNST, prior malignancy or other cancer requiring treatment with chemotherapy or radiation therapy; (2) A life-threatening illness, medical condition, or organ system dysfunction; (3) Have had prior treatment with a MEKi, Ras or Raf inhibitor; (4) Patients currently participating in any clinical trials at the time of enrollment or initiation of selumetinib.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:CASE_ONLY
  • 時間の展望:PROSPECTIVE

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
NF1-PN patient demographics and disease characteristics at baseline and during selumetinib treatment
時間枠:From baseline to 24 months after first dose of selumetinib

Race,ethnicity,Gender,Date of birth,Relationship of caregiver to patient

From baseline to 24 months after first dose of selumetinib
NF1-PN disease characteristics
時間枠:From baseline to 24 months after first dose of selumetinib

Date of diagnosis or age at diagnosis of NF1, Date of diagnosis or age at diagnosis of PN, NF1 clinical diagnosis criteria and related manifestations, NF1 and PN diagnostic tests and results, Morbidities related to PN

From baseline to 24 months after first dose of selumetinib
Selumetinib treatment profile
時間枠:From baseline to 24 months after first dose of selumetinib

Dose and dose modification, start and stop dates, dose interruption and discontinuation, reasons for interruption, discontinuation and dose modification.

From baseline to 24 months after first dose of selumetinib
Physician's qualitative assessment of disease status for clinically significant PN and overall disease status
時間枠:From baseline to 24 months after first dose of selumetinib

Improving with treatment, progression, stable

From baseline to 24 months after first dose of selumetinib
NF1 disease status
時間枠:From baseline to 24 months after first dose of selumetinib

Presence, number, size (Diameter - centimeters or cubic centimeters of volume) and location (neck/trunk, trunk and limbs, limbs only, head only, head and neck, trunk only) of PN/ optic pathway gliomas/ café-au-lait macules/ cutaneous neurofibroma.

From baseline to 24 months after first dose of selumetinib

二次結果の測定

結果測定
メジャーの説明
時間枠
To assess tumor activity of NF1-PN upon discontinuation of selumetinib
時間枠:From baseline to 24 months after first dose of selumetinib

Time to tumor regrowth after treatment discontinuation.

From baseline to 24 months after first dose of selumetinib
To describe the course of patients' disease and treatment following discontinuation of selumetinib
時間枠:From baseline to 24 months after first dose of selumetinib

The course of patients' disease and treatment following discontinuation of selumetinib will be analyzed descriptively.

From baseline to 24 months after first dose of selumetinib
To describe caregiver- or patient-reported treatment adherence
時間枠:From baseline to 24 months after first dose of selumetinib

The adherence to treatment will be derived from data collected in the medication diary. Persistence of treatment will be assessed by the time from first dose to discontinuation date and will be analyzed by survival analysis methods.

From baseline to 24 months after first dose of selumetinib
To determine whether patients treated with selumetinib have a clinically meaningful decrease in pain intensity associated with pain scale
時間枠:From baseline to 24 months after first dose of selumetinib

The evolution of pain measured with NRS-11 compared with baseline. Time to pain onset after discontinuation. PROs scales.

From baseline to 24 months after first dose of selumetinib

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Xin Ni, PhD、Beijing Children hospital

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年12月20日

一次修了 (推定)

2027年6月30日

研究の完了 (推定)

2027年6月30日

試験登録日

最初に提出

2023年11月8日

QC基準を満たした最初の提出物

2023年12月18日

最初の投稿 (実際)

2023年12月19日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月23日

QC基準を満たした最後の更新が送信されました

2026年9月22日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal

Vivli.org. All requests will be evaluated as per the AZ disclosure commitment:

https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

IPD 共有時間枠

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD 共有アクセス基準

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する